The Montreal Clinical Research Institute (IRCM) is delighted to announce that Dr. Michel Cayouette – Director of the Cellular Neurobiology Research Unit at IRCM and Full Professor-Researcher in the Department of Medicine at the Université de Montréal – was awarded a Tier 1 Canada Research Chair in Retinal Biology and Vision Restoration, one of the country’s most prestigious distinctions recognizing world-leading researchers through the Canadian Institutes of Health Research (CIHR). This new Chair is supported with $200,000 annually for seven years.
This major recognition, supported by the Université de Montréal, will enable Dr. Cayouette and his team to intensify promising research efforts aimed at developing treatments for the thousands of people affected by degenerative retinal diseases that currently have no cure.
Inherited retinal dystrophies lead to the progressive loss of photoreceptors, the specialized cells that detect light and make vision possible. While some approaches, including gene therapies, can slow the disease progression when implemented early, they cannot restore vision once these cells are lost. Dr. Cayouette’s research program seeks to overcome this major challenge by developing new strategies to regenerate or replace lost cells and ultimately restore vision.
“This Chair gives us the means to pursue fundamental questions about how the retina is built and functions under normal conditions, and how disruptions in these mechanisms lead to retinal dystrophies. By gaining a deeper understanding of the processes underlying the assembly of a healthy retina, we hope to pave the way for treatments that can, not only, slow disease progression but also restore vision in patients who currently have no therapeutic options,” said Dr. Michel Cayouette.
To achieve this ambitious goal, the researchers will leverage the latest advances in genetics, stem cell biology, imaging, and genome editing to develop innovative regenerative therapies inspired by the natural mechanisms that build a functional retina.
For the IRCM, this announcement highlights the importance of supporting excellence in fundamental research, which is essential to the development of tomorrow’s therapies.
“The discoveries that lead to the greatest medical breakthroughs originate from ambitious research programs such as Dr. Cayouette’s. This Canada Research Chair reflects Michel’s exceptional scientific excellence and underscores the importance of sustained investment in research that goes beyond understanding disease and ultimately strives for cures,” said Dr. Jean-François Côté, President and Scientific Director of IRCM.
This appointment further confirms the leading role played by the IRCM and the Université de Montréal in advancing bold, innovative biomedical research dedicated to improving human health.
